Potential novel application of dual time point suv measurements as a predictor of survival in head and neck cancer

Nuclear Medicine Communications

Volumn 26, Issue 10, 2005, Pages 861-867

  Sanghera, Bal ^a   Wong, Wai Lup ^b   Lodge, Martin A ^c   Hain, Sharon ^d   Stott, David ^a   Lowe, John ^a   Lemon, Catherine ^a   Goodchild, Kate ^a   Saunders, Michele ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MARYLAND   (United States)

^c MIDDLESEX HOSPITAL   (United Kingdom)

^d UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Dual time imaging; Head and neck cancer; Positron emission tomography; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; WHOLE BODY SCANNER;

FEMALE; FLUORODEOXYGLUCOSE F18; GREAT BRITAIN; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 26444549026     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200510000-00003     Document Type: Article

References (23)

1. Wong WL, Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol 2003; 15:461-466.
2. Goerres GW, Schmid DT, Gratz KW, von Schulthess GK, Eyrich GK. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003; 39:547-551.
3. 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004; 45:1632-1639.
4. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 2004; 91:1004-1009.
5. Oku S, Nakagawa K, Momose T, Kumakura Y, Abe A, Watanabe T, et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 2002; 16:409-416.
6. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998; 82:2227-2234.
7. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000; 18:425-428.
8. 18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-1404.
9. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002; 86:512-516.
10. Rege S, Safa AA, Chaiken L, Hoh C, Juillard G, Withers HR. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 2000; 23:164-169.
11. Thie JA, Hubner KF, Smith GT. Optimizing imaging time for improved performance in oncology PET studies. Mol Imaging Biol 2002; 4:238-244.
12. 18F-FDG for the diagnosis of thoracic malignancy. Nucl Med Commun 2003; 24:1129-1137.
13. Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003; 44:1775-1783.
14. 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumour. Ann Nucl Med 2002; 16:169-176.
15. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-1417.
16. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual Time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26:1345-1348.
17. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
18. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004; 31:590-595.
19. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004; 45:56-68.
20. Koike I, Ohmura M, Hata M, Takahashi N, Oka T, Ogino I, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys 2003; 57:1231-1238.
21. Xu M, Luk WK, Cutler PD, Digby WM. Local threshold for segmenting attenuation correction of PET imaging of the thorax. IEEE Trans Nucl Sci 1994; 41:1532-1537.
22. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13:601-609.
23. Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 1998; 25:593-597.